This article reviews the evidence for efficacy and safety of Saccharomyces boulardii(S.boulardii) for various disease indications in adults based on the peerreviewed,randomized clinical trials and pre-clinical studies...This article reviews the evidence for efficacy and safety of Saccharomyces boulardii(S.boulardii) for various disease indications in adults based on the peerreviewed,randomized clinical trials and pre-clinical studies from the published medical literature(Medline,Clinical Trial websites and meeting abstracts) between 1976 and 2009.For meta-analysis,only randomized,blinded controlled trials unrestricted by language were included.Pre-clinical studies,volunteer studies and uncontrolled studies were excluded from the review of efficacy and meta-analysis,but included in the systematic review.Of 31 randomized,placebo-controlled treatment arms in 27 trials(encompassing 5029 study patients),S.boulardii was found to be significantly efficacious and safe in 84% of those treatment arms.A meta-analysis found a significant therapeutic efficacy for S.boulardii in the prevention of antibiotic-associated diarrhea(AAD)(RR = 0.47,95% CI:0.35-0.63,P < 0.001).In adults,S.boulardii can be strongly recommended for the prevention of AAD and the traveler's diarrhea.Randomized trials also support the use of this yeast probiotic for prevention of enteral nutrition-related diarrhea and reduction of Heliobacter pylori treatment-related symptoms.S.boulardii shows promise for the prevention of C.difficile disease recurrences;treatment of irritable bowel syndrome,acute adult diarrhea,Crohn's disease,giardiasis,human immunodeficiency virus-related diarrhea;but more supporting evidence is recommended for these indications.The use of S.boulardii as a therapeutic probiotic is evidence-based for both efficacy and safety for several types of diarrhea.展开更多
目的系统评价布拉氏酵母菌治疗小儿轮状病毒肠炎的疗效和安全性。方法在万方数据知识平台、中国知网、中国生物医学文献数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane图书馆等中检索布拉氏酵母菌治疗小儿...目的系统评价布拉氏酵母菌治疗小儿轮状病毒肠炎的疗效和安全性。方法在万方数据知识平台、中国知网、中国生物医学文献数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane图书馆等中检索布拉氏酵母菌治疗小儿轮状病毒肠炎的相关文献,并追索已纳入的参考文献。对文献进行评价与资料提取,使用Stata 14.0软件进行Meta分析。结果纳入12篇文献,共1 233例患儿(626例为试验组,607例为对照组),7篇文献采用止泻时间进行评价,显示布拉氏酵母菌能够缩短小儿轮状病毒肠炎腹泻时间[SMD=-0.73,95%CI(-1.05,-0.41),I^2=75.7%];5篇文献以住院时间进行评价,显示布拉氏酵母菌能够缩短小儿轮状病毒肠炎的住院时间[SMD=-0.99,95%CI(-1.24,-0.74),I^2=56.5%];10篇文献以总有效率进行评价,显示布拉氏酵母菌能够提高小儿轮状病毒肠炎的总有效率[RR=1.26,95%CI(1.19,1.34),I^2=26.2%];仅有1篇文献报道了轻微的不良反应。结论布拉氏酵母菌治疗小儿轮状病毒肠炎疗效显著,且不良反应轻微,值得临床推广应用。展开更多
文摘This article reviews the evidence for efficacy and safety of Saccharomyces boulardii(S.boulardii) for various disease indications in adults based on the peerreviewed,randomized clinical trials and pre-clinical studies from the published medical literature(Medline,Clinical Trial websites and meeting abstracts) between 1976 and 2009.For meta-analysis,only randomized,blinded controlled trials unrestricted by language were included.Pre-clinical studies,volunteer studies and uncontrolled studies were excluded from the review of efficacy and meta-analysis,but included in the systematic review.Of 31 randomized,placebo-controlled treatment arms in 27 trials(encompassing 5029 study patients),S.boulardii was found to be significantly efficacious and safe in 84% of those treatment arms.A meta-analysis found a significant therapeutic efficacy for S.boulardii in the prevention of antibiotic-associated diarrhea(AAD)(RR = 0.47,95% CI:0.35-0.63,P < 0.001).In adults,S.boulardii can be strongly recommended for the prevention of AAD and the traveler's diarrhea.Randomized trials also support the use of this yeast probiotic for prevention of enteral nutrition-related diarrhea and reduction of Heliobacter pylori treatment-related symptoms.S.boulardii shows promise for the prevention of C.difficile disease recurrences;treatment of irritable bowel syndrome,acute adult diarrhea,Crohn's disease,giardiasis,human immunodeficiency virus-related diarrhea;but more supporting evidence is recommended for these indications.The use of S.boulardii as a therapeutic probiotic is evidence-based for both efficacy and safety for several types of diarrhea.
文摘目的系统评价布拉氏酵母菌治疗小儿轮状病毒肠炎的疗效和安全性。方法在万方数据知识平台、中国知网、中国生物医学文献数据库、维普中文科技期刊数据库、PubMed、Web of Science、Embase、Cochrane图书馆等中检索布拉氏酵母菌治疗小儿轮状病毒肠炎的相关文献,并追索已纳入的参考文献。对文献进行评价与资料提取,使用Stata 14.0软件进行Meta分析。结果纳入12篇文献,共1 233例患儿(626例为试验组,607例为对照组),7篇文献采用止泻时间进行评价,显示布拉氏酵母菌能够缩短小儿轮状病毒肠炎腹泻时间[SMD=-0.73,95%CI(-1.05,-0.41),I^2=75.7%];5篇文献以住院时间进行评价,显示布拉氏酵母菌能够缩短小儿轮状病毒肠炎的住院时间[SMD=-0.99,95%CI(-1.24,-0.74),I^2=56.5%];10篇文献以总有效率进行评价,显示布拉氏酵母菌能够提高小儿轮状病毒肠炎的总有效率[RR=1.26,95%CI(1.19,1.34),I^2=26.2%];仅有1篇文献报道了轻微的不良反应。结论布拉氏酵母菌治疗小儿轮状病毒肠炎疗效显著,且不良反应轻微,值得临床推广应用。
